The unprecedented global health crisis ignited by the COVID-19 pandemic propelled messenger RNA (mRNA) vaccines into the scientific vanguard and public consciousness, marking a pivotal moment in vaccinology. Following rigorous clinical trials, the first COVID-19 mRNA vaccine was administered on December 8, 2020, initiating a worldwide vaccination effort that would profoundly alter the course of the pandemic. Researchers subsequently leveraged sophisticated modeling techniques to estimate the monumental impact of these vaccines, concluding that they prevented at least 14.4 million deaths globally within their inaugural year of deployment. This remarkable achievement underscored the transformative potential of mRNA technology, inspiring a rapid expansion of research and development into mRNA-based vaccines for a spectrum of other infectious diseases. The mRNA Revolution and Its Unveiled Challenges The journey of mRNA vaccines from theoretical concept to life-saving intervention was nothing short of extraordinary. Decades of fundamental research laid the groundwork, but it was the urgency of the pandemic that accelerated their development and regulatory approval at an unprecedented pace. The core principle involves delivering genetic instructions (mRNA) to human cells, prompting them to produce a viral protein, typically the spike protein for SARS-CoV-2. This protein then triggers an immune response, preparing the body to fight off actual infection. The high efficacy rates demonstrated in early trials and real-world data, often exceeding 90% against symptomatic disease, solidified their status as a game-changer in public health. The success of COVID-19 mRNA vaccines spurred a global scientific race to apply this technology to other pressing health threats. Ongoing clinical trials worldwide are currently targeting a diverse array of pathogens, including the highly prevalent influenza virus, Respiratory Syncytial Virus (RSV), the persistent Human Immunodeficiency Virus (HIV), the mosquito-borne Zika virus, the ubiquitous Epstein-Barr virus, and the formidable tuberculosis bacteria. These efforts reflect a widespread optimism about mRNA’s versatility and speed in vaccine development. However, alongside these successes, the extensive real-world application of COVID-19 mRNA vaccines has also brought to light important limitations, signaling the imperative for innovative and complementary vaccine strategies. These challenges, spanning both biological efficacy and practical logistics, highlight areas where next-generation platforms could offer significant improvements. Navigating the Complexities of mRNA Vaccine Performance and Production One primary concern with COVID-19 mRNA vaccines has been the observed variability in immune protection among individuals. Factors such as age, underlying health conditions, and genetic predispositions can influence the robustness and duration of the immune response. Furthermore, the protection conferred by these vaccines, while initially strong, does not last indefinitely, necessitating booster shots to maintain optimal immunity. This issue is compounded by the relentless evolutionary pressure on SARS-CoV-2, which continually generates new variants capable of partially evading existing immune defenses. The emergence of variants like Delta and Omicron demonstrated the virus’s capacity to diminish vaccine effectiveness, leading to the frequent need for vaccine updates and reformulated boosters, a process that is resource-intensive and time-consuming. Beyond biological performance, significant practical challenges have emerged regarding the manufacturing and distribution of mRNA vaccines. The production process for these vaccines is inherently complex and expensive. It involves synthesizing delicate mRNA molecules and encapsulating them within lipid nanoparticles (LNPs), which protect the mRNA from degradation and facilitate its entry into cells. Controlling the precise number of mRNA molecules packaged into each LNP remains a technical hurdle, impacting consistency and yield. Moreover, a critical logistical barrier for mRNA vaccines has been their stringent cold-chain requirements. For instance, the Pfizer-BioNTech vaccine initially required ultra-cold storage at -70°C (-94°F), while the Moderna vaccine needed -20°C (-4°F). These extreme temperature demands pose immense challenges for global distribution, particularly in low-income countries and remote regions where specialized freezers, reliable electricity, and robust transportation infrastructure are often lacking. This "cold chain" requirement significantly inflates distribution costs and limits accessibility, exacerb exacerbating global health inequities. Additionally, while generally safe, mRNA vaccines may occasionally cause unintended off-target effects, although these are rare and typically mild. Addressing these multifaceted limitations is crucial for enhancing global preparedness and response capabilities for future infectious disease threats. Introducing DoriVac: A DNA Origami Nanotechnology Alternative In response to these complex challenges, a pioneering multidisciplinary team—comprising researchers from the Wyss Institute at Harvard University, Dana-Farber Cancer Institute (DFCI), and their partner institutions—has explored a fundamentally different and highly innovative approach. Their work centers on a novel DNA origami nanotechnology platform named DoriVac, which is engineered to function concurrently as both a vaccine and a potent adjuvant. This dual functionality represents a significant departure from traditional vaccine designs, where antigens and immune-stimulating adjuvants are often separate components. The researchers meticulously designed DoriVac vaccines to target a conserved peptide region known as HR2, which is present in the spike proteins of several highly pathogenic viruses, including SARS-CoV-2, HIV, and Ebola. This strategic targeting of a conserved region is critical, as it aims to elicit broad and long-lasting immunity that is less susceptible to viral mutation compared to targeting highly variable regions. Initial preclinical testing in mouse models yielded highly encouraging results. The SARS-CoV-2 HR2 DoriVac vaccine successfully triggered robust and comprehensive immune responses, encompassing both antibody-driven (humoral) and T cell-driven (cellular) activity. This dual activation is vital for effective protection, as antibodies primarily neutralize extracellular virus, while T cells are crucial for clearing infected cells and providing long-term immunological memory. To further validate these findings and bridge the gap between animal models and human physiology, the team employed the Wyss Institute’s cutting-edge microfluidic human Organ Chip technology. Specifically, they utilized a human lymph node-on-a-chip, an in vitro system designed to accurately simulate aspects of the human immune system. In this sophisticated model, the SARS-CoV-2 HR2 DoriVac vaccine also generated strong antigen-specific immune responses in human cells, providing crucial early indications of its potential efficacy in humans. In a direct comparative study, a DoriVac vaccine carrying the same spike protein variant as current mRNA vaccines produced a similarly strong immune activation in human models when delivered through lipid nanoparticles. However, the DNA origami vaccine showcased distinct advantages in terms of stability, demonstrating greater ease of storage and manufacture. These groundbreaking findings were recently detailed in the prestigious scientific journal Nature Biomedical Engineering. Expert Perspectives on DoriVac’s Potential Dr. William Shih, a co-corresponding author, Wyss Institute Core Faculty member, and Professor at Harvard Medical School and DFCI, whose group spearheaded the development of this novel vaccine concept, emphasized the platform’s inherent flexibility and precision. "With the DoriVac platform, we have developed an extremely flexible chassis with a number of critical advantages, including an unprecedented control over vaccine composition, and the ability to program immune recognition in targeted immune cells on a molecular level to achieve better responses," stated Dr. Shih. "Our study demonstrates DoriVac’s versatility and potential by taking a close look at the immune changes that are required to fight infectious viruses." This level of molecular control is a hallmark of DNA nanotechnology, allowing for exquisite fine-tuning of vaccine properties. The Architectural Brilliance of DNA Origami Vaccines The conceptualization and construction of DoriVac vaccines represent a triumph of DNA nanotechnology. In 2024, Dr. Shih’s team at the Wyss Institute and Dana-Farber formally introduced DoriVac as a versatile DNA nanotechnology-based vaccine platform with broad potential applications, initially focusing on cancer immunotherapy. Dr. Yang (Claire) Zeng, a pivotal leader in this endeavor and now cofounder and CEO/CTO of DoriNano, highlighted DoriVac’s unique ability to precisely present immune-stimulating adjuvant molecules to cells at the nanoscale. Earlier studies involving tumor-bearing mice provided compelling evidence that DoriVac vaccines engineered with the DNA origami structure produced significantly stronger immune responses compared to versions lacking this intricate scaffolding. This enhanced immunogenicity underscored the critical role of the origami structure in optimizing immune cell activation. DoriVac vaccines are ingeniously constructed from tiny, self-assembling square DNA nanostructures. These nanostructures are designed with remarkable precision: one side is engineered to display adjuvant molecules, which are carefully arranged at controlled nanometer distances to maximize their interaction with immune cells. The opposite side presents selected antigens, such as peptides or proteins derived from tumors or pathogens. This spatial arrangement is crucial for orchestrating a potent and targeted immune response. Dr. Zeng reflected on the origins of DoriVac’s application to infectious diseases: "While we were developing the platform for cancer applications, the COVID-19 pandemic was still moving with full force. So, the question quickly arose whether DoriVac’s superior adjuvant activity could also be leveraged in infectious disease settings." This critical pivot capitalized on the platform’s demonstrated immune-stimulating capabilities. To explore this promising avenue, Dr. Zeng, as a first and co-corresponding author on the new study, collaborated with co-first author Dr. Olivia Young, a former graduate student in Dr. Shih’s group. They joined forces with Dr. Donald Ingber’s team at the Wyss Institute, renowned for its focus on antiviral innovation, utilizing AI-driven and multiomics approaches alongside microfluidic human Organ Chip systems. Together with co-first author Dr. Longlong Si, a former postdoctoral researcher in Dr. Ingber’s lab, the researchers developed DoriVac vaccines specifically targeting SARS-CoV-2, HIV, and Ebola. These vaccines presented HR2 peptides, selected for their role as conserved antigens within the respective viral spike proteins, aiming for broader protection against viral variants. "Our analysis of the immune responses provoked by these first DoriVac vaccines in mice led to several encouraging observations, including significantly greater and broader activation of humoral and cellular immunity across a range of relevant immune cell types than what the origami-free antigens and adjuvants could produce," explained Dr. Zeng. She further elaborated on the specific immune benefits: "We found that the numbers of antibody-producing B cells, activated antigen-presenting dendritic cells (DCs), and antigen-specific memory and cytotoxic T cell types that are vital for long-term protection were all increased, especially in the case of the SARS-CoV-2 HR2." This comprehensive activation of both arms of the adaptive immune system is essential for robust and enduring protection against pathogens. Bridging the Translational Gap: From Mouse Studies to Human Models A perennial challenge in vaccine development is the translational gap between preclinical animal studies and human clinical outcomes. Immune responses observed in mice, while informative, often do not fully predict what will transpire in humans, leading to the failure of many promising treatments during costly and lengthy clinical trials. To address this critical limitation and enhance the predictability of DoriVac’s human outcomes, the research team strategically employed the human lymph node-on-a-chip (human LN Chip). This sophisticated in vitro system is engineered to mimic key aspects of the human immune system, providing a more physiologically relevant testing ground. This advanced system, further developed by co-first author Min Wen Ku and co-corresponding author Dr. Girija Goyal, Director of Bioinspired Therapeutics at the Wyss Institute, proved invaluable. Testing the SARS-CoV-2-HR2 DoriVac vaccine in the human LN Chip demonstrated its ability to effectively activate human dendritic cells (DCs) and significantly increase their production of inflammatory cytokines—critical signaling molecules that orchestrate immune responses—compared with origami-free components. Crucially, it also led to an increase in the number of CD4+ and CD8+ T cells exhibiting multiple protective functions, further bolstering the platform’s potential for successful translation to human use. Dr. Donald Ingber, a co-corresponding author, Judah Folkman Professor of Vascular Biology at Harvard Medical School and Boston Children’s Hospital, and the Hansjörg Wyss Professor of Biologically Inspired Engineering at Harvard John A. Paulson School of Engineering and Applied Sciences, underscored the significance of this approach. "The predictive capabilities of human LN Chips gave us an ideal testing ground for DoriVac vaccines and the induced, antigen-specific immune cell profiles and activities very likely reflect those that would occur in human recipients of the vaccines," Dr. Ingber stated. "This convergence of technologies enabled us to dramatically raise the chances of success for a new class of vaccines and create a new testbed for future vaccine developments." The use of human Organ Chips represents a paradigm shift in preclinical drug and vaccine testing, offering higher fidelity to human biology. DoriVac Versus mRNA Vaccines: A Head-to-Head Comparison To firmly establish DoriVac’s competitive potential, the researchers conducted a direct comparison against the established mRNA vaccine platforms. Led by Dr. Zeng and co-author Qiancheng Xiong, the team evaluated a DoriVac vaccine presenting the full SARS-CoV-2 spike protein against commercial mRNA lipid nanoparticle (LNP) vaccines from Moderna and Pfizer/BioNTech, which encode the identical spike protein. Using a standard booster approach in mice, both vaccine types elicited remarkably similar antiviral T cell and antibody-producing B cell responses. This finding is profoundly significant, as it suggests that DoriVac can achieve comparable immunological efficacy to the current gold standard mRNA vaccines. However, as Dr. Shih highlighted, DoriVac offers distinct practical advantages that could revolutionize global vaccine distribution and accessibility. "This underscored DoriVac’s potential as a DNA nanotechnology-enabled, self-adjuvanted vaccine platform. But DoriVac vaccines have a number of other advantages: they don’t have the same cold-chain requirements as mRNA-LNP vaccines do and thus could be distributed much more effectively, especially in under-resourced regions; and they could overcome some of the enormous manufacturing complexities of LNP-formulated vaccines, to name two major ones," explained Dr. Shih. The ability to withstand less stringent storage conditions, potentially room temperature, would dramatically simplify logistics and reduce costs, making these vaccines viable for deployment in virtually any part of the world, including remote and rural communities currently underserved by existing vaccine infrastructure. Recent studies conducted by DoriNano have also indicated that DoriVac possesses a promising safety profile, a crucial factor for any new vaccine technology. Broader Implications and Future Outlook for Global Health The emergence of the DoriVac platform carries profound implications for the future of vaccinology and global health preparedness. Its inherent flexibility, precise control over vaccine composition, and enhanced stability position it as a formidable contender in the next generation of vaccines. One of the most significant impacts could be on global health equity. By mitigating the need for ultra-cold storage and simplifying manufacturing, DoriVac could dramatically improve vaccine accessibility in low- and middle-income countries, where cold chain infrastructure is often limited or non-existent. This would democratize access to life-saving vaccines, ensuring that populations in under-resourced regions are not left behind during future pandemics or ongoing disease prevention efforts. Furthermore, DoriVac’s ability to precisely present conserved antigens, as demonstrated with the HR2 peptide, offers a potential pathway to developing "universal" vaccines that provide broader and more durable protection against evolving pathogens. This could reduce the need for frequent vaccine updates, streamlining public health responses and potentially preventing future pandemics from spiraling out of control. The platform’s origin in cancer research also points to its broader therapeutic potential, suggesting it could be adapted for a range of immunological applications beyond infectious diseases, including targeted cancer immunotherapies. The successful translation of this technology is being spearheaded by DoriNano, a company co-founded by Dr. Yang (Claire) Zeng, which aims to bring DoriVac from preclinical studies to clinical applications. This commercialization pathway is essential for ensuring that this promising technology can eventually benefit patients worldwide. The research was a highly collaborative effort, with contributions from numerous researchers including Sylvie Bernier, Hawa Dembele, Giorgia Isinelli, Tal Gilboa, Zoe Swank, Su Hyun Seok, Anjali Rajwar, Amanda Jiang, Yunhao Zhai, LaTonya Williams, Caleb Hellman, Chris Wintersinger, Amanda Graveline, Andyna Vernet, Melinda Sanchez, Sarai Bardales, Georgia Tomaras, Ju Hee Ryu, and Ick Chan Kwon. The study received vital financial support from a diverse array of organizations, including the Director’s Fund and Validation Project program of the Wyss Institute; the Claudia Adams Barr Program at DFCI; the National Institutes of Health (U54 grant CA244726-01); the US-Japan CRDF global fund (grant R-202105-67765); the National Research Foundation of Korea (grants MSIT, RS-2024-00463774, RS-2023-00275456); the Intramural Research Program of the Korea Institute of Science and Technology (KIST); and the Bill and Melinda Gates Foundation (INV-002274). This extensive network of funding and collaboration underscores the broad scientific interest and significant potential attributed to the DoriVac platform, positioning it as a pivotal advancement in the ongoing global fight against infectious diseases. Post navigation This common vaccine cuts heart risk nearly in half in new study
